Modelling in preclinical and clinical drug development

被引：1

作者：

Balant, LP ^{[1
]}

Gex-Fabry, M ^{[1
]}

机构：

[1] Univ Geneva, Dept Psychiat, CH-1225 Chene Bourg, Switzerland

来源：

PHARMACOKINETIC OPTIMIZATION IN DRUG RESEARCH: BIOLOGICAL, PHYSICOCHEMICAL, AND COMPUTATIONAL STRATEGIES | 2001年

关键词：

D O I：

10.1002/9783906390437.ch2

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：15 / 29

页数：15

共 73 条

[1] Software for population pharmacokinetics and pharmacodynamics [J].

Aarons, L .

CLINICAL PHARMACOKINETICS, 1999, 36 (04) :255-264

[2] Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies [J].

Aarons, L ;

Balant, LP ;

Mentre, F ;

Rowland, M ;

Steimer, JL ;

Vozeh, S .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 49 (04) :251-254

[3]

Aarons L., 1997, POPULATION APPROACH

[4]

BALANT LP, 1990, ADV DRUG RES, V19, P1

[5]

BEAL SL, 1982, CRIT REV BIOMED ENG, V8, P195

[6] Methodological issues in pharmacokinetic-pharmacodynamic modelling [J].

Bellissant, E ;

Sébille, V ;

Paintaud, G .

CLINICAL PHARMACOKINETICS, 1998, 35 (02) :151-166

[7]

Boxenbaum H, 1990, Adv Drug Res, V19, P139

[8]

Buchwald P, 1998, CURR MED CHEM, V5, P353

[9] Extrapolation from animals to man - The integration of pharmacokinetics and pharmacodynamics [J].

Campbell, DB .

CELLULAR AND MOLECULAR MECHANISMS OF DRUGS OF ABUSE: COCAINE, IBOGAINE, AND SUBSTITUTED AMPHETAMINES, 1996, 801 :116-135

[10] PHARMACOKINETIC-PHARMACODYNAMIC MODELING IN PRECLINICAL INVESTIGATIONS - PRINCIPLES AND PERSPECTIVES [J].

DANHOF, M ;

MANDEMA, JW ;

HOOGERKAMP, A ;

MATHOT, RAA .

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (01) :41-47

← 1 2 3 4 5 6 7 8 →